Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Parkinson's Disease

Free Subscription Articles published in Neurology Retrieve available abstracts of 193 articles: HTML format

Single Articles

June 2024
1. DI LUCA DG, Perlmutter JS
   Time for Clinical Dopamine Transporter Scans in Parkinsonism?: Not DAT Yet.
   Neurology. 2024;102:e209558.
   PubMed    
   
   
   
2. HOY CW, Chiong W
   The Ethical Landscape of Prodromal Parkinson Disease: Considerations for Shared Decision-Making and Health Equity.
   Neurology. 2024;102:e209522.
   PubMed    
   
   
   
3. HASTINGS A, Cullinane P, Wrigley S, Revesz T, et al
   Neuropathologic Validation and Diagnostic Accuracy of Presynaptic Dopaminergic Imaging in the Diagnosis of Parkinsonism.
   Neurology. 2024;102:e209453.
   PubMed     Abstract available
   
   
   
4. REES RN, Noyce AJ, Schrag AE
   Identification of Prodromal Parkinson Disease: We May Be Able to But Should We?
   Neurology. 2024;102:e209394.
   PubMed     Abstract available
   
   
   May 2024
5. RUS T, Cuderman A, Georgiev D
   Parkinsonism Associated With Traumatic Hemorrhage in Substantia Nigra: Role of Presynaptic Dopaminergic Imaging.
   Neurology. 2024;102:e209384.
   PubMed    
   
   
   
6. DOPPLER CEJ, Seger A, Farrher E, Regio Brambilla C, et al
   Glutamate Signaling in Patients With Parkinson Disease With REM Sleep Behavior Disorder.
   Neurology. 2024;102:e209271.
   PubMed     Abstract available
   
   
   April 2024
7. BROWN G, De Jesus S
   Bridging the Gap: Local Field Potentials Offer a Peek Into the Brain of a Person With Parkinson Disease.
   Neurology. 2024;102:e209283.
   PubMed     Abstract available
   
   
   
8. ZHAO Y, Lai Y, Konijnenberg H, Huerta JM, et al
   Association of Coffee Consumption and Prediagnostic Caffeine Metabolites With Incident Parkinson Disease in a Population-Based Cohort.
   Neurology. 2024;102:e209201.
   PubMed     Abstract available
   
   
   
9. ZHANG D, Zhou L, Lu C, Feng T, et al
   Free-Water Imaging of the Nucleus Basalis of Meynert in Patients With Idiopathic REM Sleep Behavior Disorder and Parkinson Disease.
   Neurology. 2024;102:e209220.
   PubMed     Abstract available
   
   
   March 2024
10. PARNETTI L, Paoletti FP
    Fluid Biomarkers for Trial Enrichment and Effect Monitoring in Disease-Modifying Treatments for Parkinson Disease.
    Neurology. 2024;102:e209194.
    PubMed    
    
    
    
11. HUTCHISON RM, Fraser K, Yang M, Fox T, et al
    Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial.
    Neurology. 2024;102:e209137.
    PubMed     Abstract available
    
    
    February 2024
12. TURNER RS
    Screening for Cognitive Decline in Isolated/Idiopathic REM Sleep Behavior Disorder: Which Test Is Best?
    Neurology. 2024;102:e208097.
    PubMed    
    
    
    
13. TOSIN MH, Goetz CG, Stebbins GT
    Patient With Parkinson Disease and Care Partner Perceptions of Key Domains Affecting Health-Related Quality of Life.
    Neurology. 2024;102:e208028.
    PubMed     Abstract available
    
    
    
14. COUSINS KAQ, Irwin DJ, Tropea TF, Rhodes E, et al
    Evaluation of ATN(PD) Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.
    Neurology. 2024;102:e208033.
    PubMed     Abstract available
    
    
    
15. RAHAYEL S, Postuma R, Baril AA, Misic B, et al
    (99m)Tc-HMPAO SPECT Perfusion Signatures Associated With Clinical Progression in Patients With Isolated REM Sleep Behavior Disorder.
    Neurology. 2024;102:e208015.
    PubMed     Abstract available
    
    
    January 2024
16. KAHLON S, Barton CR, Abu Libdeh A, O'Malley JA, et al
    Emerging Subspecialties: Pediatric Movement Disorders Neurology.
    Neurology. 2024;102:e208050.
    PubMed     Abstract available
    
    
    December 2023
17. ELLIOTT JE, Bryant-Ekstrand MD, Keil AT, Ligman BR, et al
    Frequency of Orthostatic Hypotension in Isolated REM Sleep Behavior Disorder.
    Neurology. 2023;101:e2545-e2559.
    PubMed     Abstract available
    
    
    
18. ISHIKAWA K
    How Certain Are You When Making the Diagnosis of Multiple System Atrophy?
    Neurology. 2023;101:1081-1082.
    PubMed     Abstract available
    
    
    November 2023
19. PURNER D, Hormozi M, Weiss D, Barbe MT, et al
    Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease.
    Neurology. 2023 Nov 1:10.1212/WNL.0000000000207858.
    PubMed     Abstract available
    
    
    October 2023
20. KRZYZANOWSKI B, Nielsen SS, Turner JR, Racette BA, et al
    Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2023 Oct 30:10.1212/WNL.0000000000207871.
    PubMed     Abstract available
    
    
    
21. DARWEESH SK, Burke JF, Peters S
    Air Pollution and Parkinson Disease: Increasing Our Risk Each Breath We Take?
    Neurology. 2023 Oct 30:10.1212/WNL.0000000000207972.
    PubMed    
    
    
    
22. ROMANOWSKA J, Bjornevik K, Cortese M, Tuominen JA, et al
    Association Between Use of Any of the Drugs Prescribed in Norway and the Subsequent Risk of Parkinson Disease: A Drug-wide Association Study.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207899.
    PubMed     Abstract available
    
    
    
23. BEAUCHAMP LC, Dore V, Villemagne VL, Xu S, et al
    Utilizing (18)F-AV-133 VMAT2 PET Imaging to Monitor Progressive Nigrostriatal Degeneration in Parkinson Disease.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207748.
    PubMed     Abstract available
    
    
    August 2023
24. RAMATCHANDIRANE B, Rebello A, Syamala DD, Ganne P, et al
    Bilateral Iris Atrophy in a Patient With Parkinsonism.
    Neurology. 2023 Aug 30:10.1212/WNL.0000000000207743.
    PubMed    
    
    
    
25. KOSKA V, Albrecht P
    Inner Retinal Thickness Changes in Prevalent and Incident Parkinson Disease: A Potential Biomarker With Prognostic Value?
    Neurology. 2023 Aug 21:10.1212/WNL.0000000000207780.
    PubMed    
    
    
    
26. WAGNER SK, Romero-Bascones D, Cortina-Borja M, Williamson DJ, et al
    Retinal Optical Coherence Tomography Features Associated With Incident and Prevalent Parkinson Disease.
    Neurology. 2023 Aug 21:10.1212/WNL.0000000000207727.
    PubMed     Abstract available
    
    
    
27. ALTAMIMI R, Aldhalaan H, Tous E, Nicolas-Jilwan M, et al
    Teaching NeuroImages: The Putaminal Eye, A Highly Characteristic Imaging Feature of MEGDEL Syndrome.
    Neurology. 2023 Aug 21:10.1212/WNL.0000000000207823.
    PubMed    
    
    
    
28. PARNETTI L, Bellomo G
    Advances in Diagnosis and Prognosis of Parkinson Disease: Value of Cerebrospinal Fluid Proteomics.
    Neurology. 2023 Aug 16:10.1212/WNL.0000000000207724.
    PubMed    
    
    
    
29. TSUKITA K, Sakamaki-Tsukita H, Kaiser S, Zhang L, et al
    High-Throughput CSF Proteomics and Machine Learning to Identify Proteomic Signatures for Parkinson Disease Development and Progression.
    Neurology. 2023 Aug 16:10.1212/WNL.0000000000207725.
    PubMed     Abstract available
    
    
    
30. FRANKLIN GL
    A Letter From a Wise Man With Parkinson Disease.
    Neurology. 2023 Aug 1:10.1212/WNL.0000000000207660.
    PubMed    
    
    
    July 2023
31. CAMICIOLI RM, Colosimo C
    Neuropsychiatric Symptoms and Parkinson Disease: Are We Looking Carefully Enough?
    Neurology. 2023 Jul 31:10.1212/WNL.0000000000207722.
    PubMed    
    
    
    
32. LEE YG, Park M, Jeong SH, Baik K, et al
    Association of Neuropsychiatric Symptom Profiles With Cognitive Decline in Patients With Parkinson Disease and Mild Cognitive Impairment.
    Neurology. 2023 Jul 31:10.1212/WNL.0000000000207623.
    PubMed     Abstract available
    
    
    
33. BENARROCH E
    What Is the Role of the Intralaminar Thalamic Input to the Striatum and Its Potential Implications in Parkinson Disease?
    Neurology. 2023;101:118-123.
    PubMed    
    
    
    
34. AGRAWAL S, Leurgans SE, Nag S, Oveisgharan S, et al
    Effects of Cerebrovascular and Lewy Body Pathology on Parkinsonian Signs in Community-Dwelling Older Adults.
    Neurology. 2023 Jul 12:10.1212/WNL.0000000000207497.
    PubMed     Abstract available
    
    
    June 2023
35. 
    Cutaneous alpha-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease.
    Neurology. 2023 Jun 30:10.1212/WNL.0000000000207614.
    PubMed    
    
    
    
36. NELSON PT, Jicha GA
    Surprising Synergy Between Cerebrovascular and Lewy Body Disease in Parkinsonism.
    Neurology. 2023 Jun 21:10.1212/WNL.0000000000207572.
    PubMed    
    
    
    
37. ZHANG Y, Zhang Y, Mao C, Jiang Z, et al
    Association of Cortical Gyrification With Imaging and Serum Biomarkers in Patients With Parkinson Disease.
    Neurology. 2023 Jun 2:10.1212/WNL.0000000000207410.
    PubMed     Abstract available
    
    
    May 2023
38. WANG L, Zhou C, Zhang W, Zhang M, et al
    Association of Cortical and Subcortical Microstructure with Clinical Progression and Fluid Biomarkers in Patients With Parkinson Disease.
    Neurology. 2023 May 18:10.1212/WNL.0000000000207408.
    PubMed     Abstract available
    
    
    
39. PORTUGAL B, Artaud F, Degaey I, Roze E, et al
    Association of Physical Activity and Parkinson Disease in Women: Long-term Follow-up of the E3N Cohort Study.
    Neurology. 2023 May 17:10.1212/WNL.0000000000207424.
    PubMed     Abstract available
    
    
    
40. CHAHINE LM, Darweesh SKL
    Physical Activity and the Risk of Parkinson Disease: Moving in the Right Direction.
    Neurology. 2023 May 17:10.1212/WNL.0000000000207527.
    PubMed    
    
    
    
41. IRANZO A, Mammana A, Munoz-Lopetegi A, Dellavalle S, et al
    Misfolded alpha-Synuclein Assessment in the Skin and CSF by RT-QuIC in Isolated REM Sleep Behavior Disorder.
    Neurology. 2023;100:e1944-e1954.
    PubMed     Abstract available
    
    
    April 2023
42. BRUMM MC, Pierz KA, Lafontant DE, Caspell-Garcia C, et al
    Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older.
    Neurology. 2023;100:e1691-e1701.
    PubMed     Abstract available
    
    
    
43. PARNETTI L, Bellomo G
    On the Track of alpha-Synuclein in the Body: Skin Biopsies for Diagnosing Synucleinopathies?
    Neurology. 2023;100:691-692.
    PubMed    
    
    
    
44. DI LUCA DG, Luo S, Liu H, Cohn M, et al
    Racial and Ethnic Differences in Health-Related Quality of Life for Individuals with Parkinson Disease Across Centers of Excellence.
    Neurology. 2023 Apr 5:10.1212/WNL.0000000000207247.
    PubMed     Abstract available
    
    
    February 2023
45. REYNOLDS EL, Gallagher G, Hill CE, Banerjee M, et al
    Costs and Utilization of New-to-Market Neurologic Medications.
    Neurology. 2023;100:e884-e898.
    PubMed     Abstract available
    
    
    
46. BECKER S, Bode M, Liepelt-Scarfone I
    Author Response: Cognitive-Driven Activities of Daily Living Impairment as a Predictor for Dementia in Parkinson Disease: A Longitudinal Cohort Study.
    Neurology. 2023;100:400.
    PubMed    
    
    
    
47. KASTEN M
    Reader Response: Cognitive-Driven Activities of Daily Living Impairment as a Predictor for Dementia in Parkinson Disease: A Longitudinal Cohort Study.
    Neurology. 2023;100:399-400.
    PubMed    
    
    
    
48. LEWIS A, Ganesh A, Galetta S
    Editors' Note: Cognitive-Driven Activities of Daily Living Impairment as a Predictor for Dementia in Parkinson Disease: A Longitudinal Cohort Study.
    Neurology. 2023;100:399.
    PubMed    
    
    
    January 2023
49. GIBBONS C, Wang N, Rajan S, Kern D, et al
    Cutaneous alpha-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease.
    Neurology. 2023 Jan 19:10.1212/WNL.0000000000206772.
    PubMed     Abstract available
    
    
    
50. MORO E, Romito LM
    Unilateral Focused Ultrasound Subthalamotomy for Parkinson Disease: Long-term Efficacy and Safety.
    Neurology. 2023 Jan 11:10.1212/WNL.0000000000206896.
    PubMed    
    
    
    
51. MARTINEZ-FERNANDEZ R, Natera-Villalba E, Manez Miro JU, Rodriguez-Rojas R, et al
    Prospective Long-term Follow-up of Focused Ultrasound Unilateral Subthalamotomy for Parkinson Disease.
    Neurology. 2023 Jan 11:10.1212/WNL.0000000000206771.
    PubMed     Abstract available
    
    
    December 2022
52. BOCK MA, Vittinghoff E, Bahorik AL, Leng Y, et al
    Cognitive and Functional Trajectories in Older Adults With Prediagnostic Parkinson Disease.
    Neurology. 2022 Dec 29:10.1212/WNL.0000000000206762.
    PubMed     Abstract available
    
    
    
53. BARRIO IR, Miki Y, Jaunmuktane ZT, Warner T, et al
    Association Between Orthostatic Hypotension and Dementia in Patients With Parkinson Disease and Multiple System Atrophy.
    Neurology. 2022 Dec 16:10.1212/WNL.0000000000201659.
    PubMed     Abstract available
    
    
    
54. PALMA JA, Cortelli P
    Blood Pressure and Risk of Dementia in Parkinson Disease and Multiple System Atrophy: Should You Buy the Dip in Such a Volatile Market?
    Neurology. 2022 Dec 16:10.1212/WNL.0000000000206803.
    PubMed    
    
    
    November 2022
55. 
    Impulsivity Trait Profiles in Patients With Cerebellar Ataxia and Parkinson Disease.
    Neurology. 2022 Nov 29:10.1212/WNL.0000000000201691.
    PubMed    
    
    
    October 2022
56. KIM R, Choi S, Byun K, Kang N, et al
    Association of Early Weight Change With Cognitive Decline in Patients With Parkinson Disease.
    Neurology. 2022 Oct 19. pii: WNL.0000000000201404.
    PubMed     Abstract available
    
    
    
57. ALDRIDGE CM
    Low Glucocerebrosidase Activity Predicts Dementia in Parkinson Disease: Less Is Not More!
    Neurology. 2022 Oct 18. pii: WNL.0000000000201575.
    PubMed    
    
    
    
58. FREQUIN HL, Schouten J, Verschuur CVM, Suwijn SR, et al
    Levodopa Response in Patients With Early Parkinson Disease: Further Observations of the LEAP Study.
    Neurology. 2022 Oct 17. pii: WNL.0000000000201448.
    PubMed     Abstract available
    
    
    
59. OFTEDAL L, Maple-Grodem J, Dalen I, Tysnes OB, et al
    Association of CSF Glucocerebrosidase Activity With the Risk of Incident Dementia in Patients With Parkinson Disease.
    Neurology. 2022 Oct 17. pii: WNL.0000000000201418.
    PubMed     Abstract available
    
    
    
60. KIM R, Lee TL, Lee H, Ko DK, et al
    Effects of Exercise on Depressive Symptoms in Patients With Parkinson Disease: A Meta-analysis.
    Neurology. 2022 Oct 11. pii: WNL.0000000000201453.
    PubMed     Abstract available
    
    
    
61. PRASUHN J, Gottlich M, Ebeling B, Kourou S, et al
    Assessment of Bioenergetic Deficits in Patients With Parkinson Disease and Progressive Supranuclear Palsy Using 31P-MRSI.
    Neurology. 2022 Oct 4. pii: WNL.0000000000201288.
    PubMed     Abstract available
    
    
    
62. CHUNG SJ, Kim YJ, Kim YJ, Lee HS, et al
    Association Between White Matter Networks and the Pattern of Striatal Dopamine Depletion in Patients With Parkinson Disease.
    Neurology. 2022 Oct 4. pii: WNL.0000000000201269.
    PubMed     Abstract available
    
    
    
63. PORTUGAL B, Artaud F, Domenighetti C, Roze E, et al
    Body Mass Index, Abdominal Adiposity, and Incidence of Parkinson Disease in French Women From the E3N Cohort Study.
    Neurology. 2022 Oct 3. pii: WNL.0000000000201468.
    PubMed     Abstract available
    
    
    September 2022
64. SIEGLER JE 3RD, Galetta S
    Editors' Note: Association of Statins With Cerebral Atherosclerosis and Incident Parkinsonism in Older Adults.
    Neurology. 2022;99:585.
    PubMed    
    
    
    
65. OVEISGHARAN S, Bennett DA, Buchman AS
    Author Response: Association of Statins With Cerebral Atherosclerosis and Incident Parkinsonism in Older Adults.
    Neurology. 2022;99:586.
    PubMed    
    
    
    
66. KELLER DL
    Reader Response: Association of Statins With Cerebral Atherosclerosis and Incident Parkinsonism in Older Adults.
    Neurology. 2022;99:585.
    PubMed    
    
    
    
67. SASAKI R, Morimoto S, Ozawa F, Okano H, et al
    APOE Alleles With Tau and Abeta Pathology In Patients With Amyotrophic Lateral Sclerosis and Parkinsonism-Dementia Complex in the Kii Peninsula.
    Neurology. 2022 Sep 21. pii: WNL.0000000000201156.
    PubMed     Abstract available
    
    
    
68. MAJBOUR N, Aasly J, Abdi I, Ghanem S, et al
    Disease-Associated alpha-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage.
    Neurology. 2022 Sep 12. pii: WNL.0000000000201199.
    PubMed     Abstract available
    
    
    
69. BECKER S, Bode M, Brockmann K, Gasser T, et al
    Cognitive-Driven Activities of Daily Living Impairment as a Predictor for Dementia in Parkinson Disease: A Longitudinal Cohort Study.
    Neurology. 2022 Sep 2. pii: WNL.0000000000201201.
    PubMed     Abstract available
    
    
    August 2022
70. ZHANG Y, He X, Mo C, Liu X, et al
    Association Between Microbial Tyrosine Decarboxylase Gene and Levodopa Responsiveness in Patients With Parkinson Disease.
    Neurology. 2022 Aug 31. pii: WNL.0000000000201204.
    PubMed     Abstract available
    
    
    
71. LEWIS A, Galetta S
    Editors' Note: Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease.
    Neurology. 2022;99:403.
    PubMed    
    
    
    
72. TSUKITA K, Sakamaki-Tsukita H, Takahashi R
    Author Response: Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
    Neurology. 2022;99:402.
    PubMed    
    
    
    
73. BRENNER SR
    Reader Response: Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease.
    Neurology. 2022;99:403.
    PubMed    
    
    
    
74. LEWIS A, Galetta S
    Editors' Note: Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
    Neurology. 2022;99:401.
    PubMed    
    
    
    
75. GRIPPE TC, Marras C, Rafferty M, Lang AE, et al
    Reader Response: Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
    Neurology. 2022;99:401-402.
    PubMed    
    
    
    
76. LIN CH, Chen SJ, Kuo CH
    Author Response: Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease.
    Neurology. 2022;99:404.
    PubMed    
    
    
    
77. TOSSERAMS A, Keijsers N, Kapelle W, Kessels RPC, et al
    Evaluation of Compensation Strategies for Gait Impairment in Patients With Parkinson Disease.
    Neurology. 2022 Aug 25. pii: WNL.0000000000201159.
    PubMed     Abstract available
    
    
    
78. SAUNDERS-PULLMAN R, Ortega RA, Wang C, Raymond D, et al
    Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the LRRK2 G2019S Variant.
    Neurology. 2022;99:e814-e823.
    PubMed     Abstract available
    
    
    
79. CROTTY GF, Schwarzschild MA
    What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs.
    Neurology. 2022;99.
    PubMed     Abstract available
    
    
    
80. MOLSBERRY SA, Hughes KC, Schwarzschild MA, Ascherio A, et al
    Who to Enroll in Parkinson Disease Prevention Trials? The Case for Composite Prodromal Cohorts.
    Neurology. 2022;99.
    PubMed     Abstract available
    
    
    
81. MIRELMAN A, Siderowf A, Chahine L
    Outcome Assessment in Parkinson Disease Prevention Trials: Utility of Clinical and Digital Measures.
    Neurology. 2022;99.
    PubMed     Abstract available
    
    
    
82. SEIBYL JP, Kuo P
    What Is the Role of Dopamine Transporter Imaging in Parkinson Prevention Clinical Trials?
    Neurology. 2022;99.
    PubMed    
    
    
    
83. MACKLIN EA, Coffey CS, Brumm MC, Seibyl JP, et al
    Statistical Considerations in the Design of Clinical Trials Targeting Prodromal Parkinson Disease.
    Neurology. 2022;99.
    PubMed     Abstract available
    
    
    
84. POSTUMA RB
    Neuroprotective Trials in REM Sleep Behavior Disorder: The Way Forward Becomes Clearer.
    Neurology. 2022;99.
    PubMed     Abstract available
    
    
    
85. BERG D, Crotty GF, Keavney JL, Schwarzschild MA, et al
    Path to Parkinson Disease Prevention: Conclusion and Outlook.
    Neurology. 2022;99.
    PubMed     Abstract available
    
    
    
86. NIOTIS K, West AB, Saunders-Pullman R
    Who to Enroll in Parkinson Disease Prevention Trials? The Case for Genetically At-Risk Cohorts.
    Neurology. 2022;99.
    PubMed     Abstract available
    
    
    
87. JANSSEN DAALEN JM, Schootemeijer S, Richard E, Darweesh SKL, et al
    Lifestyle Interventions for the Prevention of Parkinson Disease: A Recipe for Action.
    Neurology. 2022;99.
    PubMed     Abstract available
    
    
    
88. GROVER S, Kumar Sreelatha AA, Pihlstrom L, Domenighetti C, et al
    Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease: Evidence From the COURAGE-PD Consortium.
    Neurology. 2022;99:e698-e710.
    PubMed     Abstract available
    
    
    
89. CROTTY GF, Keavney JL, Alcalay RN, Marek K, et al
    Planning for Prevention of Parkinson Disease: Now Is the Time.
    Neurology. 2022;99.
    PubMed     Abstract available
    
    
    
90. PALMA JA
    Reader Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
    Neurology. 2022;99:260.
    PubMed    
    
    
    
91. KANG UJ, Nakamura K, Zhuang X
    Reader Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
    Neurology. 2022;99:258-259.
    PubMed    
    
    
    
92. CHRISTINE CW, Richardson RM, Van Laar A, Fine EM, et al
    Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
    Neurology. 2022;99:260-261.
    PubMed    
    
    
    
93. CHRISTINE CW, Richardson RM, Fine EM, Khwaja OS, et al
    Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
    Neurology. 2022;99:259.
    PubMed    
    
    
    
94. SIEGLER JE, Galetta S
    Editors' Note: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
    Neurology. 2022;99:258.
    PubMed    
    
    
    
95. BELLOMO G, De Luca CMG, Paoletti FP, Gaetani L, et al
    alpha-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward.
    Neurology. 2022;99:195-205.
    PubMed     Abstract available
    
    
    July 2022
96. TSUKITA K, Sakamaki-Tsukita H, Takahashi R
    Author Response: Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
    Neurology. 2022;99:132.
    PubMed    
    
    
    
97. LEWIS A, Galetta S
    Editors' Note: Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
    Neurology. 2022;99:131.
    PubMed    
    
    
    
98. DARWEESH SKL, De Vries N, Bloem BR
    Reader Response: Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
    Neurology. 2022;99:131-132.
    PubMed    
    
    
    
99. GUPTA VK
    Reader Response: Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
    Neurology. 2022;99:133.
    PubMed    
    
    
    
100. TSUKITA K, Sakamaki-Tsukita H, Takahashi R
     Author Response: Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
     Neurology. 2022;99:133-134.
     PubMed    
     
     
     
101. TAKEUCHI H, Masaki K, Ogata H, Nagata S, et al
     Teaching NeuroImages: Reversible Parkinsonism Caused by Lumboperitoneal Shunt Overdrainage.
     Neurology. 2022 Jul 8. pii: WNL.0000000000200994.
     PubMed    
     
     
     June 2022
102. BERGQUIST F, Ehrnebo M, Nyholm D, Johansson A, et al
     Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease.
     Neurology. 2022 Jun 15. pii: WNL.0000000000200804.
     PubMed     Abstract available
     
     
     
103. YOON EJ, Lee JY, Kim H, Yoo D, et al
     Brain Metabolism Related to Mild Cognitive Impairment and Phenoconversion in Patients With Isolated REM Sleep Behavior Disorder.
     Neurology. 2022;98:e2413-e2424.
     PubMed     Abstract available
     
     
     
104. WANG L, Wu P, Brown P, Zhang W, et al
     Association of Structural Measurements of Brain Reserve With Motor Progression in Patients With Parkinson Disease.
     Neurology. 2022 Jun 6. pii: WNL.0000000000200814.
     PubMed     Abstract available
     
     
     May 2022
105. TALMAN L
     Quality of Life for Patients With Parkinson Disease.
     Neurology. 2022;98:e2293-e2295.
     PubMed    
     
     
     
106. GROVER S, Ashwin AKS, Pihlstrom L, Domenighetti C, et al
     Genome-wide Association and Meta-analysis of Age-at-Onset in Parkinson Disease: Evidence From COURAGE-PD Consortium.
     Neurology. 2022 May 26. pii: WNL.0000000000200699.
     PubMed     Abstract available
     
     
     
107. AVENALI M, Vaghi G, De Icco R, Grillo V, et al
     Pearls & Oy-sters: Marionette walk in Parkinson's disease: a rare dyskinetic-dystonic gait pattern complication improved by visual cueing.
     Neurology. 2022 May 18. pii: WNL.0000000000200714.
     PubMed     Abstract available
     
     
     April 2022
108. LIN J, Li C, Shang H
     Teaching Video NeuroImage: Oculogyric Crises in a 12-Year-Old Girl With Rapid-Onset Dystonia Parkinsonism.
     Neurology. 2022 Apr 28. pii: WNL.0000000000200584.
     PubMed    
     
     
     
109. DELGADO-ALVARADO M, Gutierrez-Gonzalez A, Marques-Llano S, Riancho J, et al
     Parkinsonism Associated With Striatal Enlarged Perivascular Spaces.
     Neurology. 2022 Apr 28. pii: WNL.0000000000200547.
     PubMed    
     
     
     
110. CHEN TX, Roy Lin CY, Aumann MA, Yan Y, et al
     Impulsivity Trait Profiles in Patients With Cerebellar Ataxia and Parkinson Disease.
     Neurology. 2022 Apr 15. pii: WNL.0000000000200349.
     PubMed     Abstract available
     
     
     
111. MYERS PS, O'Donnell JL, Jackson JJ, Lessov-Schlaggar CN, et al
     Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease.
     Neurology. 2022 Apr 13. pii: WNL.0000000000200344.
     PubMed     Abstract available
     
     
     
112. BOCK MA, Brown EG, Zhang L, Tanner C, et al
     Association of Motor and Nonmotor Symptoms With Health-Related Quality of Life in a Large Online Cohort of People With Parkinson Disease.
     Neurology. 2022 Apr 13. pii: WNL.0000000000200113.
     PubMed     Abstract available
     
     
     
113. HALLOWAY S, Desai P, Beck T, Aggarwal N, et al
     Association of Neurofilament Light With the Development and Severity of Parkinson Disease.
     Neurology. 2022 Apr 13. pii: WNL.0000000000200338.
     PubMed     Abstract available
     
     
     March 2022
114. OVEISGHARAN S, Yu L, Barnes LL, Agrawal S, et al
     Association of Statins With Cerebral Atherosclerosis and Incident Parkinsonism in Older Adults.
     Neurology. 2022 Mar 23. pii: WNL.0000000000200182.
     PubMed     Abstract available
     
     
     February 2022
115. GONCALVES A, Oliveira J, Simoes R, Canas N, et al
     Hemiparkinsonism Secondary to Giant Aneurysm.
     Neurology. 2022;98:325-326.
     PubMed    
     
     
     
116. CHUNG SJ, Kim YJ, Jung JH, Lee HS, et al
     Association Between White Matter Connectivity and Early Dementia in Patients With Parkinson Disease.
     Neurology. 2022 Feb 21. pii: WNL.0000000000200152.
     PubMed     Abstract available
     
     
     
117. ARMENTEROS PR, Kapetanovic S, Lopez SG, Vazquez-Lorenzo E, et al
     Pearls & Oy-sters: Arteriovenous Malformation With Sinus Thrombosis and Thalamic Hemorrhage: Unusual Cause of Parkinsonism and Dementia.
     Neurology. 2022 Feb 4. pii: WNL.0000000000200016.
     PubMed     Abstract available
     
     
     January 2022
118. ZHANG X, Molsberry SA, Yeh TS, Cassidy A, et al
     Intake of Flavonoids and Flavonoid-Rich Foods, and Mortality Risk Among Individuals With Parkinson Disease: A Prospective Cohort Study.
     Neurology. 2022 Jan 26. pii: WNL.0000000000013275.
     PubMed     Abstract available
     
     
     
119. PAAKINAHO A, Koponen M, Tiihonen M, Kauppi M, et al
     Disease-Modifying Antirheumatic Drugs and Risk of Parkinson Disease: Nested Case-Control Study of People With Rheumatoid Arthritis.
     Neurology. 2022 Jan 21. pii: WNL.0000000000013303.
     PubMed     Abstract available
     
     
     
120. MAK MK, Schwarz HB
     Could Exercise Be the Answer? Disease-Modification With Long-term Regular Physical Activity in Parkinson Disease.
     Neurology. 2022 Jan 12. pii: WNL.0000000000013208.
     PubMed    
     
     
     
121. TSUKITA K, Sakamaki-Tsukita H, Takahashi R
     Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
     Neurology. 2022 Jan 12. pii: WNL.0000000000013218.
     PubMed     Abstract available
     
     
     
122. PROVITERA V, Iodice V, Manganelli F, Mozzillo S, et al
     Postganglionic Sudomotor Assessment in Early Stage of Multiple System Atrophy and Parkinson Disease: A Morpho-functional Study.
     Neurology. 2022 Jan 11. pii: WNL.0000000000013300.
     PubMed     Abstract available
     
     
     
123. CHEN SJ, Chen CC, Liao HY, Lin YT, et al
     Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Parkinson Disease Patients.
     Neurology. 2022 Jan 7. pii: WNL.0000000000013225.
     PubMed     Abstract available
     
     
     
124. HWANG YJ, Alexander GC, Moore TJ, Mehta HB, et al
     Author Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
     Neurology. 2022;98:49-50.
     PubMed    
     
     
     
125. SUBBIAH P, Doshi D, Turner ME
     Reader Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
     Neurology. 2022;98:49.
     PubMed    
     
     
     
126. GANESH A, Galetta S
     Editors' Note: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
     Neurology. 2022;98:48.
     PubMed    
     
     
     December 2021
127. MAIDAN I, Hacham R, Galperin I, Giladi N, et al
     Neural Variability in the Prefrontal Cortex as a Reflection of Neural Flexibility and Stability in Patients With Parkinson Disease.
     Neurology. 2021 Dec 14. pii: WNL.0000000000013217.
     PubMed     Abstract available
     
     
     November 2021
128. PRINGSHEIM T, Day GS, Smith DB, Rae-Grant A, et al
     Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee.
     Neurology. 2021;97:942-957.
     PubMed     Abstract available
     
     
     October 2021
129. RONG S, Xu G, Liu B, Sun Y, et al
     Trends in Mortality From Parkinson Disease in the United States, 1999-2019.
     Neurology. 2021 Oct 27. pii: WNL.0000000000012826.
     PubMed     Abstract available
     
     
     
130. BESSE-PINOT E, Pereira B, Durif F, Fantini ML, et al
     Preoperative REM Sleep Behavior Disorder and Subthalamic Deep Brain Stimulation Outcome in Parkinson Disease 1 Year After Surgery.
     Neurology. 2021 Oct 19. pii: WNL.0000000000012862.
     PubMed     Abstract available
     
     
     
131. YOON SY, Park YH, Lee HJ, Kang DR, et al
     Lifestyle Factors and Parkinson Disease Risk: Korean Nationwide Cohort Study With Repeated Health Screening Data.
     Neurology. 2021 Oct 14. pii: WNL.0000000000012942.
     PubMed     Abstract available
     
     
     
132. CHRISTINE CW, Richardson RM, Van Laar AD, Thompson ME, et al
     Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
     Neurology. 2021 Oct 14. pii: WNL.0000000000012952.
     PubMed     Abstract available
     
     
     
133. RUSZ J, Tykalova T, Novotny M, Zogala D, et al
     Defining Speech Subtypes in De Novo Parkinson Disease: Response to Long-term Levodopa Therapy.
     Neurology. 2021 Oct 4. pii: WNL.0000000000012878.
     PubMed     Abstract available
     
     
     September 2021
134. SAMOTUS O, Chen R, Jog M
     Changes in Cortical Excitability and Parkinson Tremor After Botulinum Toxin Therapy.
     Neurology. 2021 Sep 8. pii: WNL.0000000000012662.
     PubMed     Abstract available
     
     
     
135. TOSSERAMS A, Wit L, Sturkenboom IHWM, Nijkrake MJ, et al
     Perception and Use of Compensation Strategies for Gait Impairment by Persons With Parkinson Disease.
     Neurology. 2021 Sep 8. pii: WNL.0000000000012633.
     PubMed     Abstract available
     
     
     
136. HANTIKAINEN E, Trolle Lagerros Y, Bonn S
     Author Response: Dietary Antioxidants and the Risk of Parkinson Disease: The Swedish National March Cohort.
     Neurology. 2021;97:511-512.
     PubMed    
     
     
     
137. KAWADA T
     Reader Response: Dietary Antioxidants and the Risk of Parkinson Disease: The Swedish National March Cohort.
     Neurology. 2021;97:511.
     PubMed    
     
     
     
138. MATAR E, White SR, Taylor JP, Thomas A, et al
     Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months.
     Neurology. 2021;97:e1031-e1040.
     PubMed     Abstract available
     
     
     
139. CHIEN HF, Rodriguez RD, Bonifati V, Nitrini R, et al
     Neuropathologic Findings in a Patient With Juvenile-Onset Levodopa Responsive Parkinsonism Due to ATP13A2 Mutation.
     Neurology. 2021 Sep 2. pii: WNL.0000000000012705.
     PubMed     Abstract available
     
     
     August 2021
140. 
     PARK2, PINK1, and DJ1 in patients with early-onset Parkinson's disease in four European countries.
     Neurology. 2021 Aug 31. pii: WNL.0000000000012715.
     PubMed    
     
     
     
141. PILOTTO A, Romagnolo A, Scalvini A, Masellis M, et al
     Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders.
     Neurology. 2021;97:e814-e824.
     PubMed     Abstract available
     
     
     
142. HWANG YJ, Alexander GC, An H, Moore TJ, et al
     Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
     Neurology. 2021 Aug 13. pii: WNL.0000000000012601.
     PubMed     Abstract available
     
     
     
143. ALI F
     Pimavanserin: A Friend or Foe in Parkinson Disease Psychosis.
     Neurology. 2021 Aug 13. pii: WNL.0000000000012656.
     PubMed    
     
     
     
144. CHOU KL, Martello J, Atem J, Elrod M, et al
     Quality Improvement in Neurology: 2020 Parkinson Disease Quality Measurement Set Update.
     Neurology. 2021;97:239-245.
     PubMed    
     
     
     June 2021
145. PRASUHN J, Prasuhn M, Fellbrich A, Strautz R, et al
     Association of Locus Coeruleus and Substantia Nigra Pathology With Cognitive and Motor Functions in Patients With Parkinson Disease.
     Neurology. 2021 Jun 29. pii: WNL.0000000000012444.
     PubMed     Abstract available
     
     
     
146. 
     Cross-Sectional Profile of Most Bothersome Problems as Reported Directly by Individuals With Parkinson's Disease (2697).
     Neurology. 2021 Jun 22. pii: WNL.0000000000012412.
     PubMed    
     
     
     
147. BOVE F, Mulas D, Cavallieri F, Castrioto A, et al
     Long-term Outcomes (15 Years) After Subthalamic Nucleus Deep Brain Stimulation in Patients With Parkinson Disease.
     Neurology. 2021 Jun 2. pii: WNL.0000000000012246.
     PubMed     Abstract available
     
     
     May 2021
148. GANDHI AB, Onukwugha E, Albarmawi H, Johnson A, et al
     Healthcare Resource Utilization Associated With Parkinson Disease Among Medicare Beneficiaries.
     Neurology. 2021 May 27. pii: WNL.0000000000012290.
     PubMed     Abstract available
     
     
     
149. SHIN JH, Lee JY, Kim YK, Yoon EJ, et al
     Parkinson Disease-Related Brain Metabolic Patterns and Neurodegeneration in Isolated REM Sleep Behavior Disorder.
     Neurology. 2021 May 19. pii: WNL.0000000000012228.
     PubMed     Abstract available
     
     
     
150. BEACH T, Chahine LM, Adler CH, Mollenhauer B, et al
     Author Response: In Vivo Distribution of alpha-Synuclein in Multiple Tissues and Biofluids in Parkinson Disease.
     Neurology. 2021;96:965-967.
     PubMed    
     
     
     
151. GIBBONS C, Donadio V, Sommer C, Liguori R, et al
     Reader Response: In Vivo Distribution of alpha-Synuclein in Multiple Tissues and Biofluids in Parkinson Disease.
     Neurology. 2021;96:964-965.
     PubMed    
     
     
     
152. IRWIN D, Saint-Hilaire M
     In Vivo Detection of Underlying Synucleinopathies: Are We There Yet?
     Neurology. 2021;96:925-926.
     PubMed    
     
     
     
153. DONADIO V, Wang Z, Incensi A, Rizzo G, et al
     In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC.
     Neurology. 2021;96:e2513-e2524.
     PubMed     Abstract available
     
     
     
154. MCCUSKER EA, Loy CT
     Prevalent Nonmotor Symptoms Associated With Huntington Disease: Challenging to Interpret and With Early Impact on Function.
     Neurology. 2021;96:875-876.
     PubMed    
     
     
     
155. KIM R, Park S, Yoo D, Jun JS, et al
     Association of Physical Activity and APOE Genotype With Longitudinal Cognitive Change in Early Parkinson Disease.
     Neurology. 2021;96:e2429-e2437.
     PubMed     Abstract available
     
     
     
156. HONG Z, Tian C, Stewart T, Aro P, et al
     Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying alpha-Synuclein-Containing Extracellular Vesicles.
     Neurology. 2021;96:e2332-e2345.
     PubMed     Abstract available
     
     
     April 2021
157. RIOU A, Houvenaghel JF, Dondaine T, Drapier S, et al
     Functional Role of the Cerebellum in Parkinson Disease: A PET Study.
     Neurology. 2021 Apr 28. pii: WNL.0000000000012036.
     PubMed     Abstract available
     
     
     
158. DONG Y, Cheng X, Dong Q
     Teaching NeuroImages: Parkinsonism Presenting With Watershed Pattern Lesions.
     Neurology. 2021 Apr 26. pii: WNL.0000000000012056.
     PubMed    
     
     
     
159. LAMOTTE G, Benarroch EE
     What Is the Clinical Correlation of Cardiac Noradrenergic Denervation in Parkinson Disease?
     Neurology. 2021;96:748-753.
     PubMed    
     
     
     March 2021
160. RABER J, Darweesh SKL, Savica R
     Physical Activity May Reduce Apolipoprotein E4-Associated Cognitive Decline in Parkinson Disease.
     Neurology. 2021 Mar 31. pii: WNL.0000000000011851.
     PubMed    
     
     
     
161. TANG X, Zhang Y, Liu D, Hu Y, et al
     Association of Gyrification Pattern, White Matter Changes, and Phenotypic Profile in Patients With Parkinson Disease.
     Neurology. 2021 Mar 25. pii: WNL.0000000000011894.
     PubMed     Abstract available
     
     
     
162. HACKER ML, Konrad PE, Davis TL, Charles D, et al
     Author Response: Deep Brain Stimulation in Early-Stage Parkinson Disease: Five-Year Outcomes.
     Neurology. 2021;96:592.
     PubMed    
     
     
     
163. SIDIROPOULOS C
     Reader Response: Deep Brain Stimulation in Early-Stage Parkinson Disease: Five-Year Outcomes.
     Neurology. 2021;96:591-592.
     PubMed    
     
     
     
164. CHARLES D, Hacker ML, Davis TL, Konrad PE, et al
     Author Response: Deep Brain Stimulation in Early-Stage Parkinson Disease: Five-Year Outcomes.
     Neurology. 2021;96:591.
     PubMed    
     
     
     
165. FASANO A, Bhowmick SS
     Reader Response: Deep Brain Stimulation in Early-Stage Parkinson Disease: Five-Year Outcomes.
     Neurology. 2021;96:590-591.
     PubMed    
     
     
     
166. SIEGLER JE, Galetta S
     Editors' Note: Deep Brain Stimulation in Early-Stage Parkinson Disease: Five-Year Outcomes.
     Neurology. 2021;96:590.
     PubMed    
     
     
     
167. CHUNG SJ, Yoo HS, Shin NY, Park YW, et al
     Perivascular Spaces in the Basal Ganglia and Long-term Motor Prognosis in Newly Diagnosed Parkinson Disease.
     Neurology. 2021 Mar 2. pii: WNL.0000000000011797.
     PubMed     Abstract available
     
     
     February 2021
168. LO C, Arora S, Ben-Shlomo Y, Barber TR, et al
     Olfactory Testing in Parkinson's Disease & REM Behavior Disorder: A Machine Learning Approach.
     Neurology. 2021 Feb 24. pii: WNL.0000000000011743.
     PubMed     Abstract available
     
     
     
169. KANG X, Ploner A, Pedersen NL, Bandres-Ciga S, et al
     Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian Randomization Study.
     Neurology. 2021 Feb 19. pii: WNL.0000000000011630.
     PubMed     Abstract available
     
     
     
170. PARK KW, Lee EJ, Lee JS, Jeong J, et al
     Machine Learning Based Automatic Rating for Cardinal Symptoms of Parkinson.
     Neurology. 2021 Feb 10. pii: WNL.0000000000011654.
     PubMed     Abstract available
     
     
     
171. PARK JH, Lee CW, Nam MJ, Kim H, et al
     Association of High-density Lipoprotein Cholesterol Variability and the Risk of Developing Parkinson's Disease.
     Neurology. 2021 Feb 3. pii: WNL.0000000000011553.
     PubMed     Abstract available
     
     
     
172. PES GM, Park YM, Sechi GP
     Cholesterol trafficking in the brain: Are we overlooking an important risk factor for Parkinson's disease?
     Neurology. 2021 Feb 3. pii: WNL.0000000000011595.
     PubMed    
     
     
     January 2021
173. HANTIKAINEN E, Lagerros YT, Ye W, Serafini M, et al
     Dietary antioxidants and the risk of Parkinson Disease: The Swedish National March Cohort.
     Neurology. 2021 Jan 6. pii: WNL.0000000000011373.
     PubMed     Abstract available
     
     
     December 2020
174. 
     Correction: Cultural disparities in deep brain stimulation (DBS) decision making in patients with Parkinson disease (PD) (1713).
     Neurology. 2020 Dec 22. pii: WNL.0000000000011240.
     PubMed    
     
     
     
175. MAPLE-GRODEM J, Dalen I, Tysnes OB, Macleod AD, et al
     Association of GBA Genotype with Motor and Functional Decline in Newly Diagnosed Patients with Parkinsons Disease.
     Neurology. 2020 Dec 21. pii: WNL.0000000000011411.
     PubMed     Abstract available
     
     
     
176. SHIN JH, Lee JY, Kim YK, Shin SA, et al
     Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder.
     Neurology. 2020;95:e3081-e3092.
     PubMed     Abstract available
     
     
     
177. PYATIGORSKAYA N, Yahia-Cherif L, Valabregue R, Gaurav R, et al
     Parkinson Disease Propagation Using MRI Biomarkers and Partial Least Squares Path Modeling.
     Neurology. 2020 Dec 4. pii: WNL.0000000000011155.
     PubMed     Abstract available
     
     
     November 2020
178. BECKER S, Granert O, Timmers M, Pilotto A, et al
     Association of hippocampal subfields, CSF biomarkers and cognition in non-demented Parkinson's disease patients.
     Neurology. 2020 Nov 20. pii: WNL.0000000000011224.
     PubMed     Abstract available
     
     
     
179. HIRATA K, Yokota T, Miura Y
     Teaching-Neuroimages: Parkinsonism secondary to a metastatic lesion involving the substantia nigra.
     Neurology. 2020 Nov 9. pii: WNL.0000000000011162.
     PubMed    
     
     
     October 2020
180. WALDVOGEL D, Baumann CR
     Author response: Beware of deep water after subthalamic deep brain stimulation.
     Neurology. 2020;95:760.
     PubMed    
     
     
     
181. SIDIROPOULOS C
     Reader response: Beware of deep water after subthalamic deep brain stimulation.
     Neurology. 2020;95:759-760.
     PubMed    
     
     
     
182. WALDVOGEL D, Baumann CR
     Author response: Beware of deep water after subthalamic deep brain stimulation.
     Neurology. 2020;95:759.
     PubMed    
     
     
     
183. BOUCA-MACHADO R, Neves M, Pona-Ferreira F, Ferreira JJ, et al
     Reader response: Beware of deep water after subthalamic deep brain stimulation.
     Neurology. 2020;95:758-759.
     PubMed    
     
     
     
184. TAN AH, Lim SY, Chong KK, Azhan A Manap MA, et al
     Probiotics for constipation in Parkinson's disease: A randomized placebo-controlled study.
     Neurology. 2020 Oct 12. pii: WNL.0000000000010998.
     PubMed     Abstract available
     
     
     
185. LIN CH, Chiu MJ
     Author response: Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
     Neurology. 2020;95:658.
     PubMed    
     
     
     
186. VAN RUMUND A, Marques TM, Esselink RAJ, Bloem BR, et al
     Reader response: Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
     Neurology. 2020;95:657-658.
     PubMed    
     
     
     
187. LEWIS A, Galetta S
     Editors' note: Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
     Neurology. 2020;95:657.
     PubMed    
     
     
     
188. FRIEDMAN JH, Goetz CG
     Apathy in Parkinson's disease: Why we should care.
     Neurology. 2020 Oct 1. pii: WNL.0000000000010961.
     PubMed    
     
     
     
189. SCOTT BM, Eisinger RS, Burns MR, Lopes J, et al
     Co-occurrence of apathy and impulse control disorders in Parkinson's disease.
     Neurology. 2020 Oct 1. pii: WNL.0000000000010965.
     PubMed     Abstract available
     
     
     September 2020
190. CROTTY GF, Maciuca R, Macklin EA, Wang J, et al
     Association of caffeine and related analytes with resistance to Parkinson's disease among LRRK2 mutation carriers: A metabolomic study.
     Neurology. 2020 Sep 30. pii: WNL.0000000000010863.
     PubMed     Abstract available
     
     
     
191. POSTUMA RB
     Dopamine imaging in prodromal Parkinson disease trials: Ready for prime time?
     Neurology. 2020 Sep 28. pii: WNL.0000000000010957.
     PubMed    
     
     
     
192. CHUNG SJ, Lee HS, Kim HR, Yoo HS, et al
     Factor analysis-derived cognitive profile predicting early dementia conversion in PD.
     Neurology. 2020;95:e1650-e1659.
     PubMed     Abstract available
     
     
     August 2020
193. COON EA, Mandrekar JN, Berini SE, Benarroch EE, et al
     Predicting phenoconversion in pure autonomic failure.
     Neurology. 2020;95:e889-e897.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge.